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Abstract
 
In an effort to identify novel therapeutic targets for autoimmunity and transplant rejection, we
developed and performed a large-scale retroviral-based functional screen to select for proteins that
inhibit antigen receptor-mediated activation of lymphocytes. In addition to known regulators of
antigen receptor signaling, we identified a novel adaptor protein, SLAP-2 which shares 36% se-
quence similarity with the known Src-like adaptor protein, SLAP. Similar to SLAP, SLAP-2 is
predominantly expressed in hematopoietic cells. Overexpression of SLAP-2 in B and T cell lines
specifically impaired antigen receptor-mediated signaling events, including CD69 surface marker
upregulation, nuclear factor of activated T cells (NFAT) promoter activation and calcium influx.
Signaling induced by phorbol myristate acetate (PMA) and ionomycin was not significantly re-
duced, suggesting SLAP-2 functions proximally in the antigen receptor signaling cascade. The
SLAP-2 protein contains an NH
 
2
 
-terminal myristoylation consensus sequence and SH3 and SH2
Src homology domains, but lacks a tyrosine kinase domain. In antigen receptor–stimulated cells,
SLAP-2 associated with several tyrosine phosphorylated proteins, including the ubiquitin ligase
Cbl. Deletion of the COOH terminus of SLAP-2 blocked function and abrogated its association
with Cbl. Mutation of the putative myristoylation site of SLAP-2 compromised its inhibitory activ-
ity and impaired its localization to the membrane compartment. Our identification of the negative
regulator SLAP-2 demonstrates that a retroviral-based screening strategy may be an efficient way to
identify and characterize the function of key components of many signal transduction systems.
Key words: SLAP-2 • SLAP • signal transduction • retrovirus • antigen receptor
 
Introduction
 
Antigen receptors on T and B cells recognize pathogens
and foreign antigens and initiate a series of intracellular bio-
chemical signaling events that result in complex biological
responses (1, 2). These signal transduction events are crucial
for T and B cell development as well as T and B cell-medi-
ated immune responses. For example, depending on the
developmental stage of the cells, the dosage, type, and du-
ration of the antigen stimulus and the presence of costimu-
latory signals, engagement of antigen receptors can lead to
either cell proliferation and differentiation or anergy and
apoptosis. In the last decade, significant progress has been
made toward understanding the mechanism by which anti-
gen receptors initiate such signaling cascades.
In the case of B lymphocytes, the B cell antigen receptor
(BCR)
 
*
 
 complex consists of ligand-binding Ig heavy and
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Abbreviations used in this paper:
 
 a.a., amino acid(s); BCR, B cell antigen re-
ceptor; BLNK, B cell linker protein; dox, doxycycline; GFP, green fluores-
cent protein; IRES, internal ribosome entry site; MAPK, mitogen-acti-
vated protein kinase; NFAT, nuclear factor of activated T cells; PKC,
protein kinase C; PLC
 
 
 
, phospholipase C-
 
 
 
; SH, Src homology; SLAP,
Src-like adapter protein; TRE, tetracycline responsive element; tTA, tetra-
cycline-dependent transactivator. 
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light chains, and signal-transducing Ig
 
 
 
 and Ig
 
 
 
 corecep-
tors. The engagement of the BCR induces tyrosine phos-
phorylation of the immunoreceptor tyrosine based activa-
tion motifs (ITAMs) present in the cytoplasmic tails of Ig
 
 
 
and Ig
 
 
 
 chains and activates multiple cytoplasmic protein
tyrosine kinases (PTKs), including Lyn (a Src family ki-
nase), Syk, and Btk (3). Analogous events occur in T cells
upon ligand binding to TCR 
 
 
 
 and 
 
 
 
 chains. Activation of
the Src family kinase Lck leads to tyrosine phosphorylation
of the ITAM motifs in the signaling CD3 and TCR
 
 
 
chains, resulting in enzymatic activation of ZAP-70. These
early biochemical events, in turn, activate a number of
downstream effector molecules, including phospholipase C
(PLC)
 
 
 
 and guanine nucleotide exchange factors for Ras-
and Rho-family GTPases (1, 2, 4). Activation of PLC
 
 
 
leads to hydrolysis of PIP
 
2
 
 to IP
 
3
 
, which elevates the intra-
cellular Ca
 
2
 
 
 
 level, and diacylglycerol, which activates pro-
tein kinase C (PKC). Activation of Ras- and Rho-family
GTPases regulates cytoskeletal rearrangement, and triggers
mitogen-activated protein kinase (MAPK) pathways. The
signaling cascades mediated by these secondary effectors ul-
timately lead to gene transcription in the nucleus and de-
termine the biological outcome of cellular activation.
It has become clear that the integration of distinct signal-
ing cascades required for lymphocyte activation depends on
the involvement of specific adaptor proteins (5–7). Adapters
are scaffolding proteins lacking enzymatic domains. How-
ever, they contain protein–protein interaction modules
such as Src homology (SH) 2 and 3 domains, pleckstrin ho-
mology (PH), and WW domains. These modules specifi-
cally recognize and bind to discrete protein structures (SH2
domains recognize and bind to phosphotyrosine in the con-
text of a specific flanking sequence; PH domains interact
with phospholipids; SH3 domains and WW domains asso-
ciate with proline-rich regions), thus allowing formation of
specific signaling complexes in the cell (8). For example, B
cell linker protein (BLNK), a B cell–specific adaptor con-
tains a COOH-terminal SH2 domain and many tyrosine
phosphorylation sites (9, 10). After BCR stimulation, the
SH2 domain of BLNK interacts with the PTK Syk, which
subsequently phosphorylates BLNK. The phosphorylation
of BLNK on multiple tyrosine residues leads to recruitment
of many critical SH2 domain-containing signaling proteins,
including PLC
 
 
 
, Btk, Vav, and Nck. The importance of
BLNK as a key scaffold for connecting different signaling
cascades is further underscored by the complete blockage of
B cell development and BCR-mediated effector function
in both BLNK-deficient mice and cell lines (11–13).
Although significant progress has been made in the past
few years in dissecting the early biochemical events initi-
ated by antigen receptors, the exact molecular mechanisms
by which these early signaling events ultimately lead to
downstream gene activation remain poorly understood. As
an improved understanding of such signaling pathways
may help to uncover better therapeutic targets for treating
transplant rejection and autoimmune diseases, it is of great
interest to identify novel key proteins that regulate these
complex processes. As an alternative to the traditional
coimmunoprecipitation and protein purification approach,
we established a large-scale functional genetic screening
method using a retroviral delivery system, which allowed
both efficient introduction of cDNAs into B and T cells
and regulatable expression of the stably integrated trans-
genes. After multiple rounds of enrichment of the desired
phenotype by fluorescence based sorting, we isolated a
cDNA encoding a novel adaptor molecule, named SLAP-2
(for Src-like adapter protein-2). We further showed that
overexpression of SLAP-2 markedly impaired antigen-
induced surface marker expression and induction of nu-
clear factor of activated T cells (NFAT) activity. Our data
strongly suggest that SLAP-2 may play an important role
in negatively regulating T and B cell-mediated effector
function. Moreover, our findings suggest that retroviral-
based functional screening can be an efficient alternative
approach for discovering key regulators in many signal
transduction pathways.
 
Materials and Methods
 
Cell Culture.
 
Human BJAB B cells, Jurkat T cells (clone N)
and Jurkat TAg cells (expressing SV40 large T antigen) were rou-
tinely cultured in RPMI 1640 supplemented with 10% fetal calf
serum (Hyclone), penicillin, and streptomycin. Phoenix A cells
(14) were grown in DMEM supplemented with 10% fetal calf se-
rum, penicillin, and streptomycin. To produce the tetracycline-
dependent transactivator (tTA)-BJAB or tTA-Jurkat cell line,
BJAB or Jurkat cells were infected with a retroviral construct
which constitutively expresses the tetracycline transactivator pro-
tein and a reporter construct which expresses LyT2 driven by a
tetracycline responsive element (TRE) (15). The tTA-BJAB or
tTA-Jurkat cell population was optimized by sorting multiple
sounds for high TRE-dependent expression of LyT2 in the ab-
sence of doxycycline (dox) and strong repression of LyT2 expres-
sion in the presence dox. The cells were also sorted for maximal
anti-IgM or anti-TCR–induced expression of CD69. Dox was
used at a final concentration of 10 ng/ml for at least 6 d to down-
regulate expression of cDNAs from the TRE promoter.
 
Transfection and Infection.
 
Phoenix A packaging cells were
transfected with retroviral vectors using calcium phosphate for 6 h
(14). After 24 h, supernatant was replaced with complete RPMI
medium and virus was allowed to accumulate for an additional 24 h.
Viral supernatant was collected, filtered through a 0.2-
 
 
 
M fil-
ter and mixed with BJAB/Jurkat cells at a density of 2.5 
 
 
 
 10
 
5
 
cells/ml. Cells were spun at room temperature for 3 h at 3,000
rpm, followed by overnight incubation at 37
 
 
 
C. Transfection and
infection efficiencies were monitored by green fluorescent protein
(GFP) expression and functional analysis was performed 2–4 d af-
ter infection. For transient transfection, various amounts of indi-
cated plasmids, plus 10 
 
 
 
g of NFAT-Luciferase plus 2 
 
 
 
g of a sec-
ond control TK Luc luciferase construct (Promega) in the case of
the reporter assay, were electroporated into 10
 
7
 
 BJAB or Jurkat
TAg cells, as described previously (16). Cells were cultured for 40 h
after transfection and assayed as indicated.
 
Constructs and Libraries.
 
Dominant negative 
 
 
 
Syk (amino
acid [a.a.] 1–402), SLAP, and SLAP-2 were cloned into the ret-
roviral pTRA-internal ribosome entry site (IRES).GFP vector
(17, 18). For generating the myristoylation mutant (SLAP-2-
myr), the second a.a. residue, Gly, was substituted with Ala using
standard PCR mutagenesis methods. The COOH-terminal trun- 
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cation mutant (SLAP-2-
 
 
 
C) containing a.a. 1–194 was generated
by a standard PCR procedure. All three versions of SLAP-2 were
COOH-terminal tagged with a FLAG-epitope (DYKDDDDK)
and cloned into both the retroviral pTRA-IRES.GFP vector and
the mammalian expression vector pEFBOS (16). Sequence simi-
larity was analyzed using MegAlign (DNA
 
*
 
).
RNA extracted from human lymph node, thymus, spleen,
and bone marrow was used to produce two cDNA libraries; one
random primed and directionally cloned and the second nondi-
rectionally cloned and provided with 3 exogenous ATG in 3
frames. cDNAs were cloned into the pTRA-exs vector giving
robust dox-regulatable transcription of cDNAs from the TRE
promoter. The total combined library complexity was 5 
 
 
 
 10
 
7
 
independent clones.
 
Stimulation.
 
For CD69 upregulation experiments, tTA-BJAB
or tTA-Jurkat cells were split to 2.5 
 
 
 
 10
 
5
 
 cells/ml 24 h before
stimulation. Cells were spun and resuspended at 5 
 
 
 
 10
 
5
 
 cells/ml
in fresh complete RPMI medium in the presence of 0.3 
 
 
 
g/ml
anti-IgM F(ab
 
 
 
)
 
2
 
 (Jackson ImmunoResearch Laboratories), 100
ng/ml C305 (anti-Jurkat clonotypic TCR [19]) hybridoma su-
pernatant or 5 ng/ml PMA for 20–26 h at 37
 
 
 
C, and then assayed
for surface CD69 expression. For tyrosine phosphorylation and
immunoprecipitation, stably infected, GFP-sorted BJAB cells
were stimulated with 25 
 
 
 
g/ml anti-IgM F(ab
 
 
 
)
 
2
 
 at 10
 
8
 
 cells/ml
for 2 min at 37
 
 
 
C in PBS. Cells were then lysed and analyzed.
 
Cell Surface Marker Analysis.
 
tTA-BJAB or Jurkat-N cells
were stained with an allophycocyanin (APC)-conjugated mouse
monoclonal anti–human CD69 antibody (Caltag) at 4
 
 
 
C for 20
min and analyzed using a FACSCalibur™ instrument (Becton
Dickinson) with CELLQuest™ software. Cell sorts were per-
formed on a MoFlo™ (Cytomation).
 
cDNA Screen.
 
Phoenix A packaging cells were transfected
with a mixture of the two tTA regulated retroviral pTRA-exs
cDNA libraries spiked with tTA-regulated pTRA-IRES.GFP-
 
 
 
Syk at an estimated 1 in 10
 
7
 
 copies as an internal positive con-
trol. Supernatant containing packaged viral particles was used to
infect tTA-BJAB cells with an efficiency of 
 
 
 
80%. After 4 d of
cDNA expression, library-infected cells were stimulated with 0.3
 
 
 
g/ml anti-IgM F(ab
 
 
 
)
 
2
 
 for 20–26 h, stained with APC-conju-
gated anti-CD69, and lowest CD69-expressing cells were isolated
using a fluorescence activated cell sorter. Sorting was repeated
over multiple rounds with a 6-d rest period between stimulations
until the population was significantly enriched for nonresponders.
Single cells were deposited from three separate rounds of sorting.
Cell clones were expanded in the presence and absence of dox,
stimulated, and analyzed for CD69 upregulation.
 
Immunoprecipitation and Immunoblots.
 
Stimulated BJAB cells
were lysed in NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 10
mM Tris-HCl, pH 7.5), protease inhibitors and phosphatase in-
hibitors, as described previously (16). After 20 min at 4
 
 
 
C, lysates
were centrifuged for 20 min at 14,000 rpm and the supernatants
were subjected to immunoprecipitation with the indicated anti-
bodies. Resulting immune complexes were washed extensively in
lysis buffer, resolved by SDS-PAGE, and transferred to PVDF
membranes. Membranes were blocked with 5% albumin in
TBST (10 mM Tris, pH 7.8, 150 mM NaCl, with 0.05% Tween
detergent). Blots were incubated with the indicated antibodies
followed by a secondary antibody conjugated with horseradish
peroxidase and then assayed by enhanced chemiluminescence as-
say (ECL kit; Amersham Pharmacia Biotech). Blots were stripped
using 0.1M glycine, pH 2.5, washed extensively in TBST buffer,
and then blocked and reprobed as described above. 4G10 mono-
clonal anti-phosphotyrosine antibodies were from UBI, anti-Cbl
and anti-CD40 were purchased from Santa Cruz Biotechnology,
Inc., anti-JNK from Cell Signaling Technology, and anti-FLAG
M2 agarose from Sigma-Aldrich.
 
Luciferase Assays.
 
Transfected BJAB or Jurkat-TAg cells (10
 
5
 
)
were aliquoted into a 96-well plate (Corning) 40 h after transfec-
tion and cultured in a final volume of 100 
 
 
 
l RPMI growth me-
dium. Cells were stimulated at 37
 
 
 
C in the growth medium con-
taining either 1 
 
 
 
g/ml of C305 hybridoma supernatant or 50 ng/
ml PMA and 1 
 
 
 
M ionomycin. After 12 h stimulation, cells were
lysed in 5
 
 
 
 lysis buffer (Promega) and assayed using the Dual Lu-
ciferase reporter kit (Promega). Luciferase activity was read on a
Luminometer (Dynex Technology) and determined in triplicates
for each experimental condition.
 
Calcium Mobilization.
 
10
 
6
 
 cells were washed in Modified Ty-
rode’s (MT) buffer (137 mM NaCl, 2.7 mM KCl, 1.8 mM
CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 20 mM Hepes, pH 7.4, 5.6 mM glucose,
0.1% BSA), resuspended in MT at 10
 
6
 
 cells/ml, and incubated
with 4 
 
 
 
g/ml indo-1 (Molecular Probes) and 4 mM Probenecid
(Sigma-Aldrich) at 37
 
 
 
C for 30 min. Cells were centrifuged and
resuspended in MT. Analysis was performed on an LSR™ Flow
Cytometer (Becton Dickinson) at 37
 
 
 
C. For stimulation, anti-
IgM F(ab
 
 
 
)
 
2
 
 was used at 1 
 
 
 
g/ml, C305 at 300 ng/ml, and iono-
mycin at 5 
 
 
 
M.
 
Cell Fractionation.
 
10
 
7
 
 BJAB cells were washed in PBSA fol-
lowed by hypotonic lysis buffer (HLB: 20 mM Tris/Cl, pH 7.5,
1 mM MgCl
 
2
 
, 2 mM EGTA, 1 mM DTT, protease and phos-
phatase inhibitors). Cells were allowed to swell for 20 min on ice
followed by lysis by Dounce homogenization. Nuclei were iso-
lated by centrifugation at 1,000 
 
g
 
 and discarded. Supernatant was
centrifuged at 53,000 
 
g
 
 for 40 min. The membrane pellet was
washed once with HLB and resuspended in RIPA buffer, fol-
lowed by dilution 1:1 in HLB. The soluble fraction was diluted
1:1 in RIPA and equal amounts of lysate were assayed.
 
Results
 
A Cell-based Assay for Identifying Regulators of Antigen Re-
ceptor Signaling.
 
Our goal was to identify cDNA inhibitors
of antigen receptor–induced signaling in a B cell line using
fluorescence-based sorting of an endogenous cell surface
activation marker. After initial evaluation of 10 different
cell surface activation markers in 5 human IgM-positive B
cell lines, CD69 upregulation in BJAB cells was chosen as
the endogenous readout of anti-IgM–induced signal trans-
duction. It has been well established that CD69 upregula-
tion is a prominent early activation event after TCR and
BCR stimulation in primary lymphocytes and thus repre-
sents a physiological marker for screening (20). To opti-
mize the system for screening, a Tet-off-based tTA gene
was stably introduced into the BJAB cells. The tTA system
delivers robust transcription of cDNAs from the TRE and
enables expression to be switched off using the tetracycline
analogue dox (15). The tTA-BJAB cell population was op-
timized by sorting multiple rounds to achieve maximal
anti-IgM–induced CD69 expression and dox-regulatable
tTA activity (see Materials and Methods).
The optimized tTA-BJAB cells were further character-
ized by expressing a dominant negative kinase-deleted ver-
sion of the B cell signaling protein Syk (
 
 
 
Syk). When
overexpressed from the TRE enhancer element, 
 
 
 
Syk sig-
nificantly reduced anti-IgM–induced CD69 expression1266 SLAP-2 Inhibits Antigen Receptor Signaling
(Fig. 1 A). This reduction was sensitive to dox, which sup-
presses the expression of  Syk (data not shown).
Genetic Screen for Regulators of Antigen Receptor Signaling in
B Cells. Two TRE-dependent retroviral cDNA expres-
sion libraries were constructed using mixed mRNAs ex-
tracted from human lymph node, thymus, spleen, and bone
marrow tissues. The libraries were pooled, spiked with a
tTA-regulated  Syk construct as an internal positive con-
trol to monitor enrichment of genetic inhibitors, and intro-
duced into tTA-BJAB cells. Cells exhibiting the lowest
anti-IgM–induced levels of CD69 expression were en-
riched by multiple rounds of fluorescence-based sorting
and grown out as single cell clones (Fig. 1 B).
A total of 1,394 single cell clones were expanded and
plated as duplicates, which were grown in the presence or
absence of dox to allow expression of TRE-dependent li-
brary cDNAs to be turned off or on. Duplicates were stim-
ulated with anti-IgM F(ab )2 and assayed for surface CD69
expression. We obtained 128 clones that consistently ex-
hibited a 50% or greater repression of anti-IgM F(ab )2-
induced CD69 expression in the absence (cDNA on)
compared with the presence (cDNA off) of dox based on
geometric means of surface CD69 immunoreactivity.
The phenotypes of three representative positive clones
(G18, 584, and 780), are illustrated in Fig. 1 C. Sequence
analysis demonstrated that clone G18 represents recovery
of the dominant negative  Syk that was spiked into the li-
brary. cDNA sequence analysis of library inserts from addi-
tional positive clones identified known negative-regulatory
enzymes, including the dual specificity phosphatase I which
dephosphorylates and inactivates MAPK and diacylglycerol
kinase   which converts diacylglycerol to phosphatidic acid
thus downregulating PKC. In addition, we isolated trun-
cated versions of signaling proteins phospholipase C -1,
Syk, and a member of the Src family of tyrosine kinases
(Hck), which have been shown to be involved in antigen
receptor–mediated signaling pathways (data not shown) (1,
2). These cDNAs lack sequences encoding the enzymatic
Figure 1. CD69 cell surface marker
screen in BJAB cells. (A) Characterization
of the tTA-BJAB cell line using dominant-
negative  Syk. The tTA-BJAB cell line was
infected with pTRA-IRES.GFP vector or a
truncated, dominant negative version of Syk
( Syk) in the same vector. Cells were stim-
ulated (stim.) with anti-IgM F(ab )2 and
stained for surface CD69 expression. In
GFP-gated control cells, fivefold antigen-
induced upregulation of CD69 expression
over the basal level was achieved. Infection
of  Syk reduced anti-IgM F(ab )2-induced
CD69 expression to 38% of the control
value and also slightly depressed basal CD69
expression. Geometric mean values of
CD69 fluorescence are shown in brackets.
(B) Screening strategy. tTA BJAB cells sta-
bly infected with pTRA cDNA libraries
were stimulated with anti-IgM F(ab )2 and
stained for CD69 surface expression. Cells
expressing the lowest levels of antigen-
induced CD69 were sorted, expanded, and
resorted until significant enrichment of
nonresponsive cells was observed. Single
cell clones were deposited from several sorts
and analyzed for anti-IgM F(ab )2-induced
CD69 upregulation in the absence (cDNA
on) and presence (cDNA off) of dox. (C)
Cell surface CD69 expression in representa-
tive positive cell clones. Unstimulated cells
(dotted line) and cells stimulated with anti-
IgM F(ab )2 (solid line) were stained with
APC-conjugated anti-CD69 antibody. Gray
line: stimulated cells stained with isotype
control-APC antibody. Inhibition of anti-
IgMF(ab )2-induced CD69 expression (top
panel) by cDNAs in clones 584, 780, and
G18 (containing spiked control  syk) is re-
versed when cells are grown in the presence
of dox (cDNA off; bottom panel).1267 Holland et al.
domains and may act as dominant-negative inhibitors. The
isolation of both the spiked  Syk and these known antigen
receptor regulators confirmed that our screening strategy
indeed led to significant enrichment of potent inhibitors of
BCR signaling.
Isolation of SLAP and a Novel SLAP Homologue, SLAP-2.
Sequencing of retroviral library cDNA inserts recovered
from clone 780 identified the Src-like adaptor protein,
SLAP (21). One function previously attributed to SLAP is
that of a negative regulator of TCR signaling, although
SLAP is also expressed in B cells (22). The isolation of the
SLAP cDNA from our screen not only validated the effi-
cacy of the functional selection used, but also established its
role in the BCR signaling pathway. Clone 584 contained a
cDNA encoding a novel protein of 261 a.a. (Fig. 2 A). Se-
quence analysis revealed that it shares structural homology
Figure 2. Cloning of a novel
inhibitory adaptor, SLAP-2. (A)
Human SLAP-2 cDNA se-
quence. The putative myristoyla-
tion site is shown in bold. Open
and solid triangles indicate the
boundaries of SH3 and SH2 do-
mains, respectively. These se-
quence data are available from
GenBank/EMBL/DDBJ under
accession no. AF326353. (B)
Alignment of human SLAP-2
and SLAP. Identical amino acids
are boxed and highlighted. Open
and solid triangles indicate the
boundaries of SH3 and SH2 do-
mains, respectively. The overall amino acid similarity between SLAP-2 and SLAP is 36%. In the SH2 and SH3 domains alone the similarity between
SLAP-2 and SLAP is 48% and between SLAP-2 and the Src family kinase Hck is 45%. (C) Northern blot analysis of SLAP-2 expression. Left: human tis-
sues and right: tumor cell lines including promyelocytic leukemia HL-60, HeLa cell S3, chronic myelogeneous leukemia K-562, lymphoblastic leukemia
MOLT-4, Burkitt’s lymphoma Raji, colorectal adenocarcinoma SW480, lung carcinoma A549, and melanoma G361. Blots were stripped and reprobed
with an actin probe (bottom panel). (D) RT-PCR of SLAP-2 from purified human primary cells. Specific SLAP-2 primers or control GAPDH primers
were used in a standard PCR reaction with cDNA templates obtained from resting (rest.) and activated (act.) CD4  T cells (stimulated with PHA),
CD19  B cells (stimulated with pokeweed mitogen), or CD14  monocytes (human blood fractions MTC panel [CLONTECH Laboratories, Inc.]).1268 SLAP-2 Inhibits Antigen Receptor Signaling
with both SLAP and Src-family kinases, and contains an
NH2-terminal myristoylation consensus sequence (MGX1–4
T/S), one SH2- and one SH3 domain, and a unique
COOH terminus, but lacks an enzymatic domain (Fig. 2
B). We therefore named it SLAP-2 for Src-like adapter
protein-2. Subsequent analyses of the remaining positive
clones identified seven other SLAP-2–containing clones
and two more SLAP-containing clones. All of the SLAP-2
and SLAP inserts contained the entire open reading frame and
were transcribed in the sense orientation, suggesting that
SLAP-2 is a negative regulator.
Northern analysis of multiple tissues indicated that
SLAP-2 was predominantly expressed in peripheral blood
leukocytes, spleen, thymus, and lung. Abundant SLAP-2
transcript was also detected in the Molt 4 human T cell
line, but not other tumor cell lines (Fig. 2 C). Reverse
transcription (RT)-PCR analysis revealed that SLAP-2
transcript was present in both BJAB and Jurkat T cell
lines, unstimulated and stimulated purified human T cells,
B cells, and monocytes, but was absent in fibroblasts and
epithelial cells (Fig. 2 D, and data not shown). Thus,
SLAP-2 appears to be a hematopoietic-specific inhibitory
signaling adaptor.
SLAP-2 Inhibits Antigen Receptor-triggered CD69 Induction
and NFAT Promoter Activation in T and B Cells. To con-
firm that the inhibitory phenotype observed in clones 584
and 780 was indeed dependent on the presence of the
cDNAs, full length SLAP-2 and SLAP cDNAs were sub-
cloned into the pTRA-IRES.GFP retroviral vector (17)
and reintroduced into parental tTA-BJAB cells (Fig. 3 A).
Coexpression of SLAP-2 or SLAP with GFP allowed for
parallel analysis of uninfected and infected cells within the
same sample, thus providing an internal control. No signif-
icant difference in basal CD69 levels was observed between
GFP-positive and GFP-negative cells within samples (data
not shown). Cross-linking of the BCR with anti-IgM led
to a  3.5-fold upregulation of CD69 expression in both
uninfected and infected cells in the vector control popula-
tion (data not shown). However, in GFP-positive cells ex-
pressing either SLAP-2 or SLAP, anti-IgM–induced CD69
expression was significantly reduced compared with vector
control or uninfected controls (Fig. 3 A) verifying that the
inhibitory phenotype could be transferred to naive cells. In
contrast, expression of SLAP-2 did not affect CD69 induc-
tion in response to PMA, which bypasses early signaling
events leading to activation of PKC and downstream sig-
naling molecules Erk 1/2 MAPKs.
SLAP has previously been shown to inhibit signaling
downstream of the TCR (22). As SLAP-2 transcript is ob-
served in T cells, we investigated whether SLAP-2 is also
capable of attenuating signals initiated from the TCR. The
pTRA-IRES.GFP retroviral vector containing SLAP-2
was reintroduced into tTA-Jurkat cells (Fig. 3 B). No sig-
nificant differences in CD69 levels were observed between
GFP-positive and GFP-negative cells within unstimulated
vector control or SLAP-infected samples (data not shown
and Fig. 3 B). In some experiments, a small decrease in
basal CD69 expression was noted in cells expressing SLAP-2
(data not shown). TCR cross-linking using C305 anti-
body upregulated CD69 expression  3.5-fold in both
GFP-positive and GFP-negative cells in the vector-infected
population (data not shown and Fig. 3 B). In contrast, ex-
pression of SLAP-2 or SLAP in Jurkat cells strongly re-
pressed C305-stimulated CD69 expression (Fig. 3 B).
SLAP-2 expression, however, only marginally affected
phorbol ester-induced CD69 levels (Fig. 3 B). Taken to-
gether, these data demonstrate that, similar to SLAP,
SLAP-2 functions as a negative regulator of antigen recep-
tor–mediated activation events that lead to CD69 upregu-
lation in both T and B cells. Moreover, the observation
that SLAP-2 does not significantly block PMA-induced
CD69 induction implies that it may function in early sig-
naling events after antigen receptor stimulation.
Antigen receptor activation contributes to the produc-
tion of many cytokines, including IL-2. Cis-acting ele-
ments in the IL-2 promoter bind proteins such as NFAT
(23). Reporter constructs containing multimers of the
NFAT element are responsive to antigen receptor–medi-
ated signaling in T and B cells and require activation of
both the calcium and MAPK pathways (23–27). To deter-
mine whether SLAP-2 plays a role in BCR and TCR-trig-
gered NFAT activation, we transiently overexpressed
SLAP-2 in BJAB and Jurkat-TAg cells and examined its ef-
fect on the NFAT-Luciferase reporter. SLAP-2 transfection
into BJAB cells resulted in a decrease in BCR-mediated
NFAT-luciferase induction. Similarly, overexpression of
SLAP-2 in Jurkat cells led to a reduction of basal NFAT ac-
tivity as well as an almost complete inhibition of TCR-
induced NFAT activation (Fig. 3 C). In contrast, it did not
block the NFAT activation in Jurkat cells induced by treat-
ment with phorbol ester and ionomycin, two pharmaco-
logical agents that bypass early antigen receptor signaling
(Fig. 3 C). To confirm that these inhibitory effects ob-
served were not due solely to pronounced overexpression
of the protein, the NFAT assay was repeated, transfecting
different quantities of DNA into Jurkat cells to produce a
titration of SLAP-2 expression (Fig. 3 D). Both low and
high SLAP-2 protein expression repressed anti-TCR–
induced NFAT promoter activation, the inhibition being
more pronounced at higher SLAP-2 concentrations. A
graded inhibitory response was also observed in a similar
transient SLAP-2 titration using upregulation of endoge-
nous CD69 as the readout (data not shown). In summary,
SLAP-2 appears to play an important receptor-proximal
role in downregulating T and B cell–mediated responses.
SLAP-2 Inhibits Antigen Receptor–induced Calcium Mobili-
zation. Cross-linking of the antigen receptor on B or T
lymphocytes initiates several well-characterized signaling
pathways including the Ras/MAPK pathway, which leads
to the phosphorylation of AP-1, and the calcium-depen-
dent pathway that contributes to the activation of NFAT.
BJAB and Jurkat cells stably infected with SLAP-2 in
pTRA-IRES.GFP or empty vector were stained with the
calcium indicator indo-1, stimulated and analyzed on a
flow cytometer allowing for simultaneous detection of cal-
cium signals in GFP-negative or -positive cell populations.1269 Holland et al.
In comparison to cells infected with vector alone, or GFP-
negative cells in the SLAP-2–infected populations, dimin-
ished antigen-induced calcium mobilization was observed
in GFP-positive BJAB and Jurkat cells expressing SLAP-2
(Fig. 4). Moreover, calcium mobilization induced by the
ionophore ionomycin was unaffected. These data suggest
that SLAP-2 functions to negatively regulate receptor
proximal signaling events which lead to mobilization of
Figure 3. SLAP-2 inhibits antigen
receptor signaling in B and T lym-
phocytes. Epitope-tagged SLAP-2
and SLAP cDNAs in the pTRA-
IRES.GFP vector or vector alone
were infected into tTA-BJAB or
Jurkat cells. Surface CD69 expres-
sion was analyzed in stimulated
GFP-negative (uninfected; dotted
line) and GFP-positive (infected;
solid line) cells by analytical gating.
The geometric means of APC-CD69
fluorescence are shown for GFP-
negative and GFP-positive cells. (A)
tTA-BJAB cells stimulated with
anti-IgM F(ab )2 or PMA. Both
SLAP-2 and SLAP significantly de-
crease anti-IgM F(ab )2-induced but
not PMA-induced CD69 expression compared with con-
trol. (B) tTA-Jurkat cells stimulated with C305 or PMA.
Both SLAP-2 and SLAP significantly decrease C305-
induced CD69 expression compared with control. (C)
NFAT promoter activation is inhibited by SLAP-2. BJAB
or Jurkat-TAg cells were transiently co-transfected with 40
 g pEFBOS-SLAP-2 or vector alone, plus an NFAT-
Luciferase reporter construct. Cells were stimulated with
anti-IgM F(ab )2, C305, or PMA plus ionomycin for 12 h,
and assayed for luciferase activity in triplicate. Fold induc-
tion of luciferase activity over the unstimulated, vector-
transfected sample is shown. The basal luciferase activity
for this experiment was  100 arbitrary light units (AU).
The data are representative of several independent experi-
ments. (D) Jurkat-TAg cells were transiently cotransfected
with 1, 2, 4, 16, or 32  g of SLAP-2 DNA and NFAT-
Luciferase reporter construct, keeping the total DNA
amount constant with empty vector. Cells were stimulated
and luciferase assays were performed as above. Equal ali-
quots of cells were analyzed by anti-FLAG Western blot
for SLAP-2 protein expression.1270 SLAP-2 Inhibits Antigen Receptor Signaling
calcium. Although anti-IgM–induced CD69 induction re-
quires predominantly the Ras/MAPK pathway (28), we
have been unable to detect modulation of Erk 1/2 MAPK
activation by SLAP-2 expression in BJAB cells by Western
blotting using phospho-specific anti-activated MAPK an-
tibodies (data not shown). However, this assay may not
be sufficiently sensitive to distinguish the small SLAP-2–
dependent decreases in MAPK activation that might occur
in these cells.
The NH2-terminal Putative Myristoylation Site and COOH-
terminal Region of SLAP-2 Are Important for Inhibition of Anti-
gen Receptor Signaling. Myristoylation has been shown to
localize signaling proteins including Src family kinases to
the membrane compartment and in many cases to be crit-
ical for their function (29). As SLAP-2 contains a putative
NH2-terminal consensus motif (MGX1–4T/S) for addition
of a myristoyl group, we generated an amino acid substi-
tution in the myristoylation motif within a FLAG-tagged
full length SLAP-2 (SLAP-2-myr) and examined its effect
on antigen receptor–induced signaling. SLAP-2-myr in
the pTRA-IRES.GFP vector was introduced into tTA-
BJAB cells. The infected GFP-positive cells were sorted
and assayed for anti-IgM–induced CD69 expression (Fig.
5 A) and SLAP-2 protein expression (Fig. 5 C). A  5-
fold upregulation of CD69 expression was observed in
vector-infected cells after BCR cross-linking (data not
shown). Expression of wild-type SLAP-2 suppressed anti-
IgM–induced CD69 levels by  2-fold (Fig. 5 A). In con-
trast, anti-IgM–induced CD69 expression in cells infected
with SLAP-2-myr was comparable to the vector control
(Fig. 5 A). Although SLAP-2-myr was expressed at
slightly lower levels than wild-type SLAP-2 (Fig. 5 C),
the complete loss of activity when the putative myristoy-
lation site was disrupted suggests that this motif may play
an important role in SLAP-2 function in BJAB cells.
Wild-type SLAP-2 and SLAP-2-myr were also expressed
in tTA-Jurkat cells at approximately equal levels (Fig. 5
D) and their effects on TCR signaling were examined
(Fig. 5 B). TCR cross-linking stimulated a  4.5-fold up-
regulation of CD69 expression in vector-infected cells
(data not shown). Expression of wild-type SLAP-2
strongly blocked upregulation of CD69 in response to
TCR cross-linking (Fig. 5 B). Once again, mutation of
the myristoylation consensus sequence significantly com-
promised this activity, suggesting that this motif is also im-
portant for SLAP-2 function in T lymphocytes.
As myristoylation targets proteins to the membrane, we
fractionated the sorted BJAB cells into membrane and cy-
toplasmic portions and asked where SLAP-2 protein is lo-
calized. The purity of membrane and supernatant fractions
was confirmed by blotting with antibodies directed against
an integral membrane protein (CD40) and a cytoplasmic
protein (JNK; Fig. 5 E). A small fraction of epitope-tagged
wild-type SLAP-2 was present in the membrane pellet,
whereas SLAP-2-myr was almost exclusively cytoplasmic
(Fig. 5 E) demonstrating that an intact myristoylation con-
sensus motif is required for association of SLAP-2 with the
membrane compartment.
The C terminus of SLAP has been proposed to perform
a number of important functions including mediating
dimerization, interacting with signaling partners (30), and
determining solubility in mild detergents (22). As this re-
gion of SLAP-2 exhibits the highest degree of sequence di-
vergence from SLAP, we expressed a truncated form of
SLAP-2 (SLAP-2- C) in tTA-BJAB cells and examined its
effect on antigen-induced CD69 upregulation. SLAP-2-
 C–expressing tTA-BJAB cells exhibited anti-IgM–
induced CD69 expression comparable to vector control
(Fig. 5 A), although some inhibition was observed when
the data was gated on the highest GFP-expressing cells
(data not shown). SLAP-2- C protein expression was sim-
ilar to that of wild-type SLAP-2 (Fig. 5 D). This result sug-
gests that although the COOH terminus is important for
Figure 4. SLAP-2 represses antigen-induced calcium mobilization in
BJAB and Jurkat cells BJAB and Jurkat cells stably expressing SLAP-2
were labeled with the calcium indicator indo-1. Cells were stimulated at
37 C on an LSR flow cytometer with UV laser, and analyzed by analyti-
cal gating on GFP. Ratio of bound/unbound indo-1 is shown over a 10-
min time course. Broken line: GFP-negative cells; solid line: GFP-posi-
tive cells. (A) BJAB cells stimulated with anti-IgM F(ab )2 followed by
ionomycin. (B) Jurkat cells stimulated with C305 followed by ionomycin.1271 Holland et al.
SLAP-2 function, its loss can be partially compensated by
higher level of protein overexpression.
SLAP-2- C was also less effective than wild-type SLAP-2
at repressing anti-TCR–induced CD69 expression in
Jurkat cells (Fig. 5 B). However, a significant level of in-
hibitory activity was retained. It is possible that the slightly
increased protein expression of SLAP-2- C compared
with wild-type SLAP-2 may contribute to this effect.
However, cell type–specific variations in SLAP-2–interact-
ing partners or signaling pathways leading to CD69 upreg-
ulation may also explain the differences in the efficacy of
SLAP-2- C in BJAB and Jurkat cells
SLAP-2 Associates with Tyrosine Phosphorylated Proteins af-
ter Antigen Receptor Engagement. Signaling through the
TCR or BCR results in a rapid increase in tyrosine phos-
phorylation of numerous intracellular proteins, initiated
Figure 5. The NH2-terminal myristoylation site and
COOH-terminal unique regions of SLAP-2 are re-
quired for inhibition of antigen receptor signaling.
Epitope-tagged wild-type SLAP-2, SLAP-2-myr, and
SLAP-2- C in the pTRA-IRES.GFP vector were sta-
bly introduced into tTA-BJAB or tTA-Jurkat cells, and
GFP-positive cells were enriched by sorting. Induced
surface CD69 expression was analyzed in vector-
infected cells (dotted line) and cells infected with wild-
type or mutant SLAP-2 (solid line) with analytical-
gating on GFP expression. The geometric means of
APC-CD69 fluorescence is shown. (A) tTA-BJAB cells
stimulated with anti-IgM F(ab )2.Wild-type (WT)
SLAP-2 reduced anti-IgM F(ab )2-induced CD69 ex-
pression by  2-fold, whereas SLAP-2-myr and SLAP-2- C resembled the
vector control. Percentage of GFP positive cells: vector 91%; wild-type
SLAP-2 89%; SLAP-2-myr 80%; SLAP-2- C 87%. (B) tTA-Jurkat cells
stimulated with C305. Wild-type SLAP-2 reduced C305-induced CD69
expression by  3-fold, whereas inhibition was compromised in cells ex-
pressing SLAP-2-myr and SLAP-2- C. Percentage of GFP-positive cells:
vector 84%; wild-type SLAP-2 46%; SLAP-2-myr 44%; SLAP-2- C 45%.
(C) Equal aliquots of infected tTA-BJAB cells were lysed and analyzed by
anti-FLAG Western blot for SLAP-2 protein expression. (D) Equal aliquots
of infected tTA-Jurkat cells were lysed and analyzed by anti-FLAG Western
blot for SLAP-2 protein expression. (E) Membrane pellet (P) and soluble
fraction (S) of wild-type SLAP-2 and SLAP-2-myr–infected tTA-BJAB
cells were immunoprecipitated (top panel) or loaded directly (center bot-
tom panels) and immunoblotted with antibodies raised against the FLAG
epitope (top panel), the integral membrane protein CD40 (center panel),
and the cytoplasmic protein JNK (bottom panel). A fraction of wild-type
SLAP-2 but not SLAP-2-myr was localized in the membrane fraction.1272 SLAP-2 Inhibits Antigen Receptor Signaling
by Src family and Syk/ZAP70 kinase activation (1, 3).
These early signaling events ultimately result in transcrip-
tional activation, upregulation of surface antigens, and
other lymphocyte effector functions. Adaptor proteins
play an important intermediary role in integrating up-
stream signals to produce biological function (6). Al-
though upon initial evaluation, no changes were discern-
able in patterns of tyrosine phosphorylation in total cell
lysates of BJAB cells overexpressing SLAP-2 (data not
shown) we further investigated the nature of SLAP-2 sig-
naling complexes. Epitope-tagged versions of SLAP-2,
SLAP-2-myr, or SLAP-2- C were immunoprecipitated
from lysates of stably expressing BJAB cells using the anti-
FLAG antibody. All three proteins became associated with
a number of tyrosine phosphorylated proteins after BCR
stimulation (Fig. 6 A), indicating that SLAP-2 indeed
participates in BCR signaling pathways. Interestingly, a
prominent phosphoprotein of  110 kD was absent in the
immunoprecipitates of SLAP-2- C (Fig. 6 A), which we
subsequently identified as the RING finger ubiquitin li-
gase Cbl (Fig. 6 B). Cbl has been previously shown to be a
negative regulator of TCR and BCR signaling pathways
(31–33). An NH2-terminal fragment of Cbl constitutively
interacts with the COOH-terminal region of SLAP as
demonstrated in both the yeast two hybrid system and
Cos-7 cells (30). In contrast, the association between
SLAP-2 and full-length Cbl in B cells was inducible after
antigen receptor stimulation. Whether SLAP-2 functions
as an inhibitory adaptor by recruiting a negative regulator
such as Cbl into the signaling complex or by competing
with a positive regulator such as a Src-family kinase re-
mains to be determined.
Discussion
In this report, we describe the identification and charac-
terization of a novel adaptor protein, SLAP-2 which con-
tains an NH2-terminal myristoylation motif and SH2 and
SH3 domain protein interaction modules. We demonstrate
that SLAP-2 functions as a negative regulator of antigen re-
ceptor–mediated signal transduction in both B and T lym-
phocytes. SLAP-2 shares amino acid and structural homol-
ogy with the Src-like adaptor protein SLAP, which has
been previously reported to downregulate TCR-mediated
signal transduction (22). Here, we reveal an additional
function for SLAP in repressing signaling though the BCR.
Figure 6. SLAP-2 associates with tyrosine phosphory-
lated proteins including Cbl after antigen stimulation. (A)
SLAP-2 associates with tyrosine phosphorylated proteins
in B cells. Sorted tTA-BJAB cells infected with epitope-
tagged wild-type (WT) SLAP-2, SLAP-2-myr, or
SLAP-2- C were stimulated with anti-IgM F(ab )2 for 2
min, lysed, and SLAP-2 was immunoprecipitated using
anti-FLAG agarose. Immunoprecipitated proteins were
subjected to SDS-PAGE and immunoblotted with anti-
phosphotyrosine antibodies. SLAP-2 associates with ty-
rosine phosphorylated proteins of  110 and 70 kD after
antigen stimulation. The  C mutant lacks the 110 kD
SLAP-2-associated phosphoprotein. Bottom panel: re-
probe with anti-FLAG. (B) SLAP-2 interacts with Cbl in
B cells. Wild-type SLAP-2, SLAP-2-myr, or SLAP-2- C
were immunoprecipitated as in (A) and immunoblotted with
anti-Cbl antibodies. Wild-type SLAP-2 and SLAP-2-myr but
not SLAP-2- C associate with Cbl after antigen stimulation.1273 Holland et al.
SLAP-2 and SLAP were isolated in a retroviral-based
functional screen for negative regulators of antigen recep-
tor–mediated signal transduction in B cells. This approach
was based upon a method previously used to clone the
novel anti-apoptosis regulator Toso in T cells (34), and
combined an efficient retroviral cDNA delivery system
with a FACS®-based sorting strategy designed to enrich ge-
netic inhibitors of BCR signaling. The successful isolation
of clones containing known modulators of antigen receptor
signal transduction pathways validated this approach. Fur-
thermore, the isolation of previously unknown regulators
of antigen receptor signaling, including SLAP-2, demon-
strates that this strategy can genetically identify novel sig-
naling pathway components based on functional activity in
lymphocyte cell lines.
Use of traditional coimmunoprecipitation and biochem-
ical purification methods as well as the yeast two hybrid
system have led to the identification of several important
kinases and adaptors including ZAP-70, linker for activa-
tion of T cells (LAT), BLNK, and SLAP (9, 21, 35, 36).
However, physical association in such assays does not pro-
vide confirmation of functional significance and cannot dis-
tinguish between positive and negative regulators. The
generation of somatic mutant cell lines deficient in trans-
duction of antigen receptor–stimulated signals is an alterna-
tive functional approach for identifying key components of
antigen-receptor signaling pathways. The central role of
the T cell signaling components, Lck, ZAP-70, SH2 do-
main-containing leukocyte protein of 76 kD (SLP-76), and
LAT, has been elegantly demonstrated in such mutant lines
(37–40). However, random mutagenesis of mammalian
cells seldom affects both alleles of a gene, and subsequent
cDNA library rescue of such mutant cell lines has been
largely unsuccessful. Our functional genetic screening strat-
egy provides a powerful method that complements these
conventional target discovery approaches and allows the
identification of novel signaling regulators and pathways
linked to specific cellular readouts.
Overexpression of either SLAP-2 or SLAP blocks anti-
gen receptor cross-linking–induced upregulation of CD69
in B and T lymphocytes as well as NFAT reporter activa-
tion in both cell types (this work and reference 22). In ad-
dition, SLAP-2 represses antigen-induced calcium flux in
both BJAB and Jurkat cells. It is difficult to conclusively
demonstrate that endogenous SLAP-2 functions as an in-
hibitor of antigen receptor signaling without antisense
knockdown or gene targeting experiments. However, we
have shown that SLAP-2 acts as a negative regulator of
TCR signaling at a wide range of SLAP-2 protein concen-
trations, suggesting that it may indeed function as an inhib-
itor at physiological expression levels.
Although the analogous roles of SLAP-2 and SLAP in
BJAB and Jurkat cells illustrate the similarities between an-
tigen receptor signaling pathways in B and T lymphocytes,
we have observed qualitative differences in the responses in
the two different cell types. First, SLAP-2 expression re-
duces antigen-stimulated CD69 levels more dramatically in
Jurkat compared with BJAB cells (28% reduction in BJAB
cells, compared with 61% in Jurkat cells) and also slightly
attenuates basal CD69 expression in the T cell line. Corre-
spondingly, expression of SLAP-2 resulted in a more pro-
nounced repression of antigen-induced calcium mobiliza-
tion in Jurkat than in BJAB cells. Second, experiments
using PMA and ionomycin to bypass early antigen receptor
signaling events suggest that SLAP-2 acts receptor proxi-
mally in both cell types. However a small effect on PMA-
induced signaling was observed in Jurkat cells, suggesting
that SLAP-2 might also influence more downstream com-
ponents of the pathway in T cells. Additional mechanistic
differences were suggested by the behavior of the SLAP-2-
 C construct in the two cell types. While the activity of
the truncated SLAP-2 was almost completely abrogated in
BJAB cells, it retained significant activity in the T cell line
suggesting a COOH terminus-independent component to
SLAP-2 function in Jurkat cells. Such cell type–specific dis-
tinctions in the outcome of SLAP-2 overexpression may
reflect differences in SLAP-2 expression levels, the expres-
sion level or identity of SLAP-2 effectors, or variation in
the potency or composition of signaling pathways em-
ployed upstream of CD69 and NFAT upregulation.
The predominantly hematopoietic expression pattern of
SLAP-2 resembles that previously reported for SLAP (22).
The role of SLAP in antigen receptor signaling is contro-
versial, since it has been described as either a negative (22)
or weak positive (30) regulator of TCR signaling using
transient reporter assays. Our data using retrovirus-medi-
ated expression and an endogenous cellular marker,
strongly suggest a negative regulatory function for SLAP in
B cells and SLAP-2 in both B and T lymphocytes. Com-
plementing experiments by Sosinowski et al., we find that
overexpression of SLAP in Jurkat cells inhibits anti-TCR–
induced CD69 upregulation and calcium flux (Fig. 3 B,
and data not shown). Analogously, SLAP-2 effectively in-
hibits signaling initiated through both the BCR and TCR
leading to CD69 upregulation and calcium flux, as well as
anti-TCR–induced NFAT activation. Sosinowski et al. re-
port that the SLAP C terminus is dispensable for inhibition
of TCR-dependent transcriptional induction from an
NFAT reporter construct in a transient overexpression sys-
tem (22). A similar trend is observed with SLAP-2 when
expressed in Jurkat cells where SLAP-2- C inhibitory ac-
tivity is only modestly compromised. In contrast, trunca-
tion of the SLAP-2 C terminus results in an almost
complete loss of repression of anti-IgM–induced CD69
upregulation in BJAB cells although this effect may be de-
pendent on SLAP-2- C protein expression level.
Although SLAP-2 and SLAP share structural homologies
within their SH2 and SH3 domains, their inhibitory mech-
anism may in part be different, possibly dictated by unique
sequences at the COOH termini of the proteins. In partic-
ular, SLAP-2 lacks sequences corresponding to the last 26
a.a. of SLAP, which have been suggested to mediate its
dimerization and insolubility in mild detergents, and to
negatively regulate interaction of SLAP with the ubiquitin
protein ligase, Cbl (22, 30). Indeed, we have experienced
no difficulty in solublizing SLAP-2 in NP-40 lysis buffer, a1274 SLAP-2 Inhibits Antigen Receptor Signaling
condition that reportedly fails to solublize SLAP (22).
Moreover, in contrast to the reported constitutive interac-
tion of SLAP with the N terminus of Cbl (30), we have
observed an inducible association between endogenous Cbl
and SLAP-2. This disparity may be due to the use of trun-
cated Cbl in these SLAP experiments, or because the in
vivo coassociation between SLAP and the Cbl N terminus
was demonstrated using overexpression in Cos-7 cells (30).
The nature of the interaction between SLAP and full
length Cbl in lymphocytes remains to be characterized;
however, functional differences between SLAP-Cbl and
SLAP-2-Cbl interactions are certainly possible.
CD69 induction is predominantly mediated by the Ras/
MAPK pathway (28) whereas NFAT activation requires
additional input from the calcium-mediated cascade. As
SLAP-2 does not significantly inhibit PMA-induced CD69
induction, or NFAT activation in response to PMA plus
ionomycin, we propose that the adaptor acts proximal to
the receptor complex, upstream of Ras activation and cal-
cium mobilization, as has been suggested for SLAP (22).
SLAP-2 effectively inhibits calcium mobilization in Jurkat
cells although a more modest effect is observed in BJAB
cells. In contrast, initial experiments failed to detect
changes in Erk 1/2 MAPK activation in the sorted SLAP-
2–expressing BJAB population compared with vector con-
trol. However, increasing the sensitivity of the assay by us-
ing cells expressing greater amounts of SLAP-2 may allow
us to detect inhibition of MAPK activity.
Consistent with the notion that SLAP-2 may act recep-
tor proximally to inhibit antigen receptor signaling, a frac-
tion of wild-type SLAP-2 was associated with the mem-
brane compartment in infected BJAB cells. Moreover,
mutation of the NH2-terminal putative myristoylation se-
quence abrogated this interaction. Myristoylation is neces-
sary but not always sufficient for stable membrane targeting
of signaling proteins (41). Indeed, the localization of
SLAP-2 is consistent with the partitioning between cyto-
plasm and membrane noted upon exogenous expression of
the myristoylated SLAP protein (42). We also observed
SLAP-2 protein accumulation in the perinuclear region of
HeLa cells transiently overexpressing the adaptor, consis-
tent with the localization to endosomes suggested for
SLAP (data not shown; 42). Significantly, the integrity of
the NH2-terminal putative myristoylation motif was found
to be important for the function of the SLAP-2 in both B
and T cell lines. It is possible that myristoylation-mediated
localization to the endosomal or plasma membrane may be
required to correctly position SLAP-2 close to receptor-
proximal signaling proteins.
SLAP is able to associate with phosphorylated tyrosine
residues on activated receptor tyrosine kinases (RTKs) (21,
43). Competition with the SH2 domains of Src family ki-
nases for receptor binding sites has been proposed to me-
diate SLAP inhibition of PDGF-induced mitogenesis in fi-
broblasts (43). It is possible that SLAP-2 and SLAP may
play a similar role in antigen receptor signaling, blocking
the interaction of Src family kinases with tyrosine phos-
phorylated signaling partners. Alternatively, the loss of in-
hibitory function of SLAP-2- C, which correlates with
failure to bind to Cbl, suggests that the association of
SLAP-2 with the RING finger ubiquitin ligase may con-
tribute to its function. Cbl has been shown to be a nega-
tive regulator of Syk/ZAP-70 and Src family kinases (31,
44, 45). One may hypothesize that SLAP-2 and SLAP act
like F-box proteins, providing a physical bridge between
Cbl and receptor proximal kinases, or may regulate Cbl
ubiquitin ligase activity toward specific targets, thereby
specifically recruiting them for degradation and resulting
in downregulation of antigen receptor–mediated re-
sponses. However, the interaction with Cbl is not suffi-
cient for SLAP-2 function, which is independently per-
turbed by mutation of the myristoylation motif, suggesting
that membrane targeting may also be required. Identifica-
tion of additional SLAP-2–associated proteins will allow a
more complete understanding of the mechanism of SLAP-2
function.
Although much recent progress has been made in under-
standing the positive cellular inputs generated by antigen
receptors, increasing evidence indicates that opposing in-
hibitory mechanisms are also vital to a proper immune re-
sponse (46). The identification of both SLAP-2 and SLAP
from a screen designed to isolate functional inhibitors of
BCR signaling strongly suggests that this family of SH2/
SH3 domain-containing adaptors plays an important role in
immune regulation by attenuating the antigen receptor ac-
tivation signal in B and T lymphocytes. The dissection of
antigen receptor signaling by such strategies may aid in the
discovery of improved therapeutic targets for treating trans-
plant rejection and autoimmunity.
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